Drug Pricing & Pharmacy
Expert articles and analysis related to drug pricing & pharmacy.
AI Summary — Last 30 Days
CMS is pushing drug pricing reform deeper into value-based payment design, extending the application window for the Medicaid GENEROUS Model amid strong manufacturer interest—an early signal that the Trump administration’s CMS is positioning outcomes-linked drug purchasing as a state Medicaid affordability tool rather than only a Medicare Part D issue. At the same time, Part D strategy is becoming more consequential for VBC stakeholders as GLP-1 coverage questions, 2027 Part D risk-adjustment changes, and MA-PD/PDP payment separation reshape plan incentives around high-cost chronic disease populations. Health systems and ACO-aligned specialty pharmacy programs are responding by embedding medication adherence, diabetes management, and specialty pharmacy care management into population health infrastructure, turning pharmacy from a cost center into a lever for downside-risk performance and total-cost-of-care management.
Related Articles
change its pharmacy care model
From newsletter: The LI Daily: Ascendiun CEO Paul Markovich wants the industry to back a policy reform movement focused on affordability, tech innovation Ascendiun CEO Paul Markovich wants the indus...
Trends in Manufacturer Coupons for Biologics: Decline in Use Despite Higher Per-Claim Value
Premier Responds to RFI on Potential 340B Rebate Model Pilot Program
Premier raised concerns that a rebate based approach to the 340B drug discount program would undermine the program and create significant risk for hospitals.
Standing up to Rising Prescription Drug Costs Increases Access to Breakthrough Medications
For millions of Americans, accessing the medications they need at prices they can afford has gotten increasingly difficult.
‘Most Favored Nation’ Drug Pricing Is An Idea Whose Time Has Come
‘Most Favored Nation’ Drug Pricing Is An Idea Whose Time Has Come Health Affairs
Trump announces tariffs as high as 100% on pharmaceuticals
President Donald Trump has announced a new pharmaceutical tariff that would impose as much as 100% on imported brand-name drugs. The executive order, announced Thursday, is to spur the production of p...
EPA to put microplastics on study list of contaminants in drinking water
The EPA names microplastics as a potential drinking water contaminant, a move that is seen as an appeal to Kennedy's MAHA movement.
STAT+: Trump announces 100% tariffs on brand-name drugs, with plenty of carveouts
The taxes are part of the president's push to rein in the pharmaceutical industry and bring manufacturing to the U.S.
STAT+: Maryland state affordability board sets its first price cap for a medicine
The board will now oversee a process to lower the cost of the type 2 diabetes medicine Jardiance by January 2027.
CMS Proposes Reforms to Speed Patient Access to Drugs
CMS Proposes Reforms to Speed Patient Access to Drugs HCI Innovation Group